Here is the pdf version:
And the power point version:
—We will start with the accepted evidence base for warfarin.
—Then move to dispel four myths about using blood-thinners in AF:
- Myth 1: Rhythm-control strategies prevent stroke.
- Myth 2: Running the INR on the low side (< 2) is an effective strategy for lowering the risk of bleeding and still getting some stroke prevention.
- Myth 3: Intermittent AF confers less stroke risk than permanent AF.
- Myth 4: Aspirin offers the AF patient (elderly or otherwise) a safer and effective strategy of stroke prevention (BAFTA Trial, AVEROS Trial, Danish Registry study (10-11)).
—Next up is this question:
- Which is the best validation score to determine stroke risk?
- CHADS2 versus the more nuanced CHA2DS2-VASc scheme.
—What is the role of dabigatran?
- Clinical Uses
- Why is ICH risk so low?
—Can AF ablation prevent stroke?
- As a rhythm control strategy, we know AF ablation beats AADrugs, but does AF ablation improve hard outcomes like stroke and death?
- CABANA Trial
—A peek at the most promising stroke prevention strategy in the near future:
- ARISTOTLE — Apixaban